Money Talks: Why weight-loss drugs will reshape the world
Money Talks from The Economist
The Lucrative Business of GLP1 Drugs
GLP1 drugs, mainly injection-based and taken weekly, have high list prices in the US, around $16,000 per year. The two leading firms selling these drugs, Novo Nordisk and Eli Lilly, have witnessed a significant increase in their market value, with speculation that one could become the first trillion-dollar pharmaceutical company. The current duopoly in the market is sustained by factors like patents, approvals, and FDA regulations, making it challenging for new entrants to compete in the short to medium term.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
